DPP4 and Respiratory tract infection: Both unadjusted and adjusted Cox proportional hazard models suggest DPP4 inhibitors are not associated with a significant increase or decrease in respiratory tract infection risk (HR = 0.94; 95% CI 0.86–1.04; adjusted HR = 0.93; 95% CI 0.84–1.04).